help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lach-Trifilieff, E.
Right arrow Articles by Walker, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lach-Trifilieff, E.
Right arrow Articles by Walker, C.

Am. J. Respir. Cell Mol. Biol., Volume 24, Number 2, February, 2001 116-122

In Vitro and In Vivo Inhibition of Interleukin (IL)-5-Mediated Eosinopoiesis by Murine IL-5Ralpha Antisense Oligonucleotide

Estelle Lach-Trifilieff, Robert A. McKay, Brett P. Monia, James G. Karras, and Christoph Walker

Novartis Horsham Research Centre, Horsham, United Kingdom; and Department of Molecular & Cellular Pharmacology, ISIS Pharmaceuticals, Carlsbad, California

The unique role of interleukin (IL)-5 in eosinophil production, activation, and localization makes this cytokine a prime target for therapeutic intervention in diseases characterized by a selective blood and tissue eosinophilia. In an attempt to block the effects of IL-5 on eosinophils, a strategy was developed to suppress the expression of the IL-5 receptor alpha  chain (IL-5Ralpha ) by antisense oligonucleotides (ASOs). IL-5Ralpha ASOs were identified which selectively and specifically suppress the expression of messenger RNA and proteins of both the membrane and the soluble form of the receptor in constitutively IL-5R-expressing murine BCL-1 cells in vitro. Moreover, these IL-5Ralpha -specific ASOs were able to selectively inhibit the IL-5-induced eosinopoesis from murine fetal liver and bone marrow cells in vitro, suggesting that these molecules may affect the development of IL-5-mediated eosinophilia in vivo. Indeed, intravenous administration of IL-5Ralpha -specific ASOs not only suppressed the bone-marrow and blood eosinophilia in mice after short-term treatment with recombinant murine IL-5 but also inhibited the development of blood and tissue eosinophilia in a ragweed-induced allergic peritonitis model. Thus, blocking the expression of IL-5Ralpha on eosinophil using ASOs may have therapeutic benefits in eosinophilic diseases such as asthma.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
L. Y. Liu, J. B. Sedgwick, M. E. Bates, R. F. Vrtis, J. E. Gern, H. Kita, N. N. Jarjour, W. W. Busse, and E. A. B. Kelly
Decreased Expression of Membrane IL-5 Receptor {alpha} on Human Eosinophils: I. Loss of Membrane IL-5 Receptor {alpha} on Airway Eosinophils and Increased Soluble IL-5 Receptor {alpha} in the Airway After Allergen Challenge
J. Immunol., December 1, 2002; 169(11): 6452 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Z. Allakhverdi, M. Allam, and P. M. Renzi
Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common beta Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma
Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 1015 - 1021.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2001 American Thoracic Society. 		  New Orleans Int'l Conf